Omics! Omics! Spent a Morning With Us!
Dr. Robison from Omics! Omics! spent the morning with us, here is what he had to say I’ve written in the past about SeqLL, the company which purchased all of the hard assets from [...]
SeqLL Installs true Single Molecule Sequencing (tSMS®) Instrument to support oncology research by Dr. David Ting, MD at the Harvard-MGH Cancer Center
Wednesday, November 3, 2017 WOBURN, MA ‐‐ SeqLL, LLC announced today that it has installed a true Single Molecule Sequencing (tSMS) Instrument at the Harvard‐MGH Cancer Center to support [...]
SeqLL Awarded SBIR to advance the development of Direct RNA Sequencing (DRS™) technology
Tuesday, July 11, 2017 WOBURN, MA — SeqLL, LLC announced today that it has been awarded a Phase I SBIR grant in the amount of $223,465 by the NIH/National Human Genome Research Institute to [...]
Case Study – The Development of a Blood Test for Coronary Artery Disease
We have recently added a Case Study Section to our website so you can see how tSMS technology is being utilized by leading researchers for multiple cutting edge applications. Here is our first [...]
Application Highlight
Application Highlight Epigenetics is the study of environmental stresses creating changes in gene expression that can be passed to offspring. These changes leave the underlying DNA sequence [...]
SeqLL Expands Early Access Program for New True Single Molecule Sequencing (tSMS™) Benchtop System
SeqLL Expands Early Access Program for New true Single Molecule Sequencing (tSMS™) Benchtop System Quantitative sequencing platform addresses limitations of other sequencing technologies. WOBURN, [...]
SeqLL Launches Early Access Program for New true Single Molecule Sequencing (tSMS™) Benchtop System
SeqLL Launches Early Access Program for New true Single Molecule Sequencing (tSMS™) Benchtop System Quantitative sequencing platform addresses limitations of other sequencing technologies. [...]